Literature DB >> 30455355

Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Daniel Weishäupl1,2,3,4, Juliane Schneider1,2,3, Barbara Peixoto Pinheiro1,2,3, Corinna Ruess1,2,3, Sandra Maria Dold1,2,3, Felix von Zweydorf5, Christian Johannes Gloeckner5,6, Jana Schmidt1,2,3, Olaf Riess1,2,3, Thorsten Schmidt7,2,3.   

Abstract

Ataxin-3 is a deubiquitinating enzyme and the affected protein in the neurodegenerative disorder Machado-Joseph disease (MJD). The ATXN3 gene is alternatively spliced, resulting in protein isoforms that differ in the number of ubiquitin-interacting motifs. Additionally, nonsynonymous SNPs in ATXN3 cause amino acid changes in ataxin-3, and one of these polymorphisms introduces a premature stop codon in one isoform. Here, we examined the effects of different ataxin-3 isoforms and of the premature stop codon on ataxin-3's physiological function and on main disease mechanisms. At the physiological level, we show that alternative splicing and the premature stop codon alter ataxin-3 stability and that ataxin-3 isoforms differ in their enzymatic deubiquitination activity, subcellular distribution, and interaction with other proteins. At the pathological level, we found that the expansion of the polyglutamine repeat leads to a stabilization of ataxin-3 and that ataxin-3 isoforms differ in their aggregation properties. Interestingly, we observed a functional interaction between normal and polyglutamine-expanded ATXN3 allelic variants. We found that interactions between different ATXN3 allelic variants modify the physiological and pathophysiological properties of ataxin-3. Our findings indicate that alternative splicing and interactions between different ataxin-3 isoforms affect not only major aspects of ataxin-3 function but also MJD pathogenesis. Our results stress the importance of considering isoforms of disease-causing proteins and their interplay with the normal allelic variant as disease modifiers in MJD and autosomal-dominantly inherited diseases in general.
© 2019 Weishäupl et al.

Entities:  

Keywords:  E3 ubiquitin ligase; alternative splicing; deubiquitylation (deubiquitination); enzyme degradation; enzyme kinetics; genetic polymorphism; neurodegenerative disease; polyglutamine disease; protein aggregation; proteomics

Mesh:

Substances:

Year:  2018        PMID: 30455355      PMCID: PMC6333899          DOI: 10.1074/jbc.RA118.005801

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  107 in total

1.  A census of human soluble protein complexes.

Authors:  Pierre C Havugimana; G Traver Hart; Tamás Nepusz; Haixuan Yang; Andrei L Turinsky; Zhihua Li; Peggy I Wang; Daniel R Boutz; Vincent Fong; Sadhna Phanse; Mohan Babu; Stephanie A Craig; Pingzhao Hu; Cuihong Wan; James Vlasblom; Vaqaar-un-Nisa Dar; Alexandr Bezginov; Gregory W Clark; Gabriel C Wu; Shoshana J Wodak; Elisabeth R M Tillier; Alberto Paccanaro; Edward M Marcotte; Andrew Emili
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

2.  Identification and functional dissection of localization signals within ataxin-3.

Authors:  Paul Michel Aloyse Antony; Simone Mäntele; Phillip Mollenkopf; Jana Boy; Ralph H Kehlenbach; Olaf Riess; Thorsten Schmidt
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

3.  Identification of proteins that interact with mammalian peptide:N-glycanase and implicate this hydrolase in the proteasome-dependent pathway for protein degradation.

Authors:  H Park; T Suzuki; W J Lennarz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

4.  Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy.

Authors:  Christine K Bailey; Isabella F M Andriola; Harm H Kampinga; Diane E Merry
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

5.  Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation.

Authors:  Bernd O Evert; Julieta Araujo; Ana M Vieira-Saecker; Rob A I de Vos; Sigrid Harendza; Thomas Klockgether; Ullrich Wüllner
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

6.  Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3).

Authors:  Conceição Bettencourt; Cristina Santos; Rafael Montiel; Maria do Carmo Costa; Pablo Cruz-Morales; Liliana Ribeiro Santos; Nelson Simões; Teresa Kay; João Vasconcelos; Patrícia Maciel; Manuela Lima
Journal:  Neurogenetics       Date:  2009-08-28       Impact factor: 2.660

7.  Regression of rat liver autophagic vacuoles by locally applied cycloheximide.

Authors:  T Papadopoulos; U Pfeifer
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

8.  Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.

Authors:  Claus Lindbjerg Andersen; Jens Ledet Jensen; Torben Falck Ørntoft
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

9.  CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.

Authors:  Thorsten Mueller; Peter Breuer; Ina Schmitt; Jochen Walter; Bernd O Evert; Ullrich Wüllner
Journal:  Hum Mol Genet       Date:  2009-06-19       Impact factor: 6.150

10.  The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability.

Authors:  Thomas M Durcan; Maria Kontogiannea; Thorhildur Thorarinsdottir; Lara Fallon; Aislinn J Williams; Ana Djarmati; Tadeu Fantaneanu; Henry L Paulson; Edward A Fon
Journal:  Hum Mol Genet       Date:  2010-10-11       Impact factor: 6.150

View more
  17 in total

1.  Differential toxicity of ataxin-3 isoforms in Drosophila models of Spinocerebellar Ataxia Type 3.

Authors:  Sean L Johnson; Jessica R Blount; Kozeta Libohova; Bedri Ranxhi; Henry L Paulson; Wei-Ling Tsou; Sokol V Todi
Journal:  Neurobiol Dis       Date:  2019-07-13       Impact factor: 5.996

2.  Pathophysiological interplay between O-GlcNAc transferase and the Machado-Joseph disease protein ataxin-3.

Authors:  Priscila Pereira Sena; Jonasz J Weber; Maxinne Watchon; Katherine J Robinson; Zinah Wassouf; Stefan Hauser; Jacob Helm; Mahkameh Abeditashi; Jana Schmidt; Jeannette Hübener-Schmid; Ludger Schöls; Angela S Laird; Olaf Riess; Thorsten Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205

3.  Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3.

Authors:  Mercedes Prudencio; Hector Garcia-Moreno; Karen R Jansen-West; Rana Hanna Al-Shaikh; Tania F Gendron; Michael G Heckman; Matthew R Spiegel; Yari Carlomagno; Lillian M Daughrity; Yuping Song; Judith A Dunmore; Natalie Byron; Björn Oskarsson; Katharine A Nicholson; Nathan P Staff; Sorina Gorcenco; Andreas Puschmann; João Lemos; Cristina Januário; Mark S LeDoux; Joseph H Friedman; James Polke; Robin Labrum; Vikram Shakkottai; Hayley S McLoughlin; Henry L Paulson; Takuya Konno; Osamu Onodera; Takeshi Ikeuchi; Mari Tada; Akiyoshi Kakita; John D Fryer; Christin Karremo; Inês Gomes; John N Caviness; Mark R Pittelkow; Jan Aasly; Ronald F Pfeiffer; Venka Veerappan; Eric R Eggenberger; William D Freeman; Josephine F Huang; Ryan J Uitti; Klaas J Wierenga; Iris V Marin Collazo; Philip W Tipton; Jay A van Gerpen; Marka van Blitterswijk; Guojun Bu; Zbigniew K Wszolek; Paola Giunti; Leonard Petrucelli
Journal:  Sci Transl Med       Date:  2020-10-21       Impact factor: 17.956

4.  Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease.

Authors:  Jonasz J Weber; Eva Haas; Yacine Maringer; Stefan Hauser; Nicolas L P Casadei; Athar H Chishti; Olaf Riess; Jeannette Hübener-Schmid
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

Review 5.  Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.

Authors:  Kritika Raj; Ravi Shankar Akundi
Journal:  Mol Neurobiol       Date:  2021-02-24       Impact factor: 5.590

6.  Removal of the Polyglutamine Repeat of Ataxin-3 by Redirecting pre-mRNA Processing.

Authors:  Craig S McIntosh; May Thandar Aung-Htut; Sue Fletcher; Steve D Wilton
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

7.  Degron capability of the hydrophobic C-terminus of the polyglutamine disease protein, ataxin-3.

Authors:  Jessica R Blount; Sean L Johnson; Kozeta Libohova; Sokol V Todi; Wei-Ling Tsou
Journal:  J Neurosci Res       Date:  2020-07-09       Impact factor: 4.164

Review 8.  Post-Translational Modifications of Deubiquitinating Enzymes: Expanding the Ubiquitin Code.

Authors:  Yanfeng Wang; Feng Wang
Journal:  Front Pharmacol       Date:  2021-06-10       Impact factor: 5.810

9.  Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice.

Authors:  Christian Barro; Jeannette Hübener-Schmid; Matthis Synofzik; Carlo Wilke; Eva Haas; Kathrin Reetz; Jennifer Faber; Hector Garcia-Moreno; Magda M Santana; Bart van de Warrenburg; Holger Hengel; Manuela Lima; Alessandro Filla; Alexandra Durr; Bela Melegh; Marcella Masciullo; Jon Infante; Paola Giunti; Manuela Neumann; Jeroen de Vries; Luis Pereira de Almeida; Maria Rakowicz; Heike Jacobi; Rebecca Schüle; Stephan A Kaeser; Jens Kuhle; Thomas Klockgether; Ludger Schöls
Journal:  EMBO Mol Med       Date:  2020-06-08       Impact factor: 12.137

10.  The Machado-Joseph disease deubiquitylase ataxin-3 interacts with LC3C/GABARAP and promotes autophagy.

Authors:  Laura K Herzog; Éva Kevei; Ricardo Marchante; Claudia Böttcher; Christian Bindesbøll; Alf Håkon Lystad; Annika Pfeiffer; Maria E Gierisch; Florian A Salomons; Anne Simonsen; Thorsten Hoppe; Nico P Dantuma
Journal:  Aging Cell       Date:  2019-10-17       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.